1.

Impaired endothelial function and arterial stiffness in patients with type 2 diabetes

Low-dose fluvastatin and valsartan added on-top of optimal therapy substantially improves arterial wall characteristics in patients with type 2 diabetes.

COBISS.SI-ID: 3616940

2.

Expression of longevity genes induced by a low-dose fluvastatin and valsartan combination with the potential to prevent/treat "aging-related disorders"

Low-dose fluvastatin and valsartan, separately and in combination, substantially increase expression of SIRT1, PRKAA, and KLOTHO genes, which may be attributed to their so far unreported pleiotropic beneficial effects. This approach could be used for prevention of ageing (and longevity genes)-related disorders.

COBISS.SI-ID: 3231867

3.

Very low-dose fluvastatin-valsartan combination decreases parameters of inflammation and oxidative stress in patients with type 1 diabetes mellitus

The approach consisting of short-term treatment with a very low-dose fluvastatin-valsartan combination acts anti-inflammatory and anti-oxidative in type 1 diabetes mellitus patients. These observations along with the improvement of arterial function support the assumption that this approach could have an important clinical benefit in type 1 diabetes mellitus patients.

COBISS.SI-ID: 33170649

4.

Improvement of arterial wall phenotype in subjects at moderate cardiovascular risk induced by very low-dose fluvastatin/valsartan combination

This pilot study revealed that intervention with low-flu/val importantly shifts the arterial wall phenotype in a lower risk direction. This improvement could be interpolated into clinical benefits that remain to be further studied.

COBISS.SI-ID: 5038252

5.

Sub-therapeutic doses of fluvastatin and valsartan are more effective than therapeutic doses in providing beneficial cardiovascular pleiotropic effects in rats

Sub-therapeutic doses of fluvastatin and valsartan are more effective in expressing cardiovascular pleiotropic effects than therapeutic doses of fluvastatin and/or valsartan. These results could be of significant clinical relevance.

COBISS.SI-ID: 4146604